Loading...
Market
Will AstraZeneca's obesity pill be FDA approved for type-2 diabetes patients by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and AstraZeneca press releases
Story
AstraZeneca's obesity pill shows 5.8% weight loss in early trial, safe and tolerable for type-2 diabetes patients, licensed from Eccogene for $2 billion
Nov 4, 2024, 06:15 PM
AstraZeneca has announced promising results from its experimental obesity pill, which showed a 5.8% reduction in body weight during an early-stage clinical trial. The company reported that the medication was well-tolerated by patients, including those with type-2 diabetes. The trial indicated that side effects were consistent with the GLP-1 drug class, and the pill was deemed safe for use. This medication was licensed from China's Eccogene for up to $2 billion, highlighting AstraZeneca's commitment to expanding its portfolio in weight-loss treatments.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
